INTERLEUKIN-1 AND INTERLEUKIN-1 ANTAGONISM IN SEPSIS, SYSTEMIC INFLAMMATORY RESPONSE SYNDROME, AND SEPTIC SHOCK

被引:140
|
作者
PRUITT, JH [1 ]
COPELAND, EM [1 ]
MOLDAWER, LL [1 ]
机构
[1] UNIV FLORIDA, COLL MED, DEPT SURG, GAINESVILLE, FL 32610 USA
来源
SHOCK | 1995年 / 3卷 / 04期
关键词
D O I
10.1097/00024382-199504000-00001
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Interleukin-1 (IL-1) is one of several proinflammatory cytokines produced during infection, sepsis, and the systemic inflammatory response syndrome (SIRS) that serves to initiate the host inflammatory response and to integrate nonspecific immunity. Many of IL-1's biologic effects are beneficial to the host in times of stress, but when produced for extended periods of time or in excessive quantities, IL-1 contributes to morbidity and mortality. In fact, excessive IL-1 production has been directly linked to the development of hypotension, shock, multi-organ system failure, hematologic dyscrasia, and death in patients and animals with sepsis, SIRS, and septic shock. Recent research interest has focused on IL-1 inhibition to improve outcome in sepsis and septic shock. This article will review the role for IL-1 in sepsis and septic shock, and the function and status of the IL-1 receptors and IL-1 receptor antagonist in modulating IL-1 actions. The results of investigations of IL-1 inhibition in animal models and in human subjects with sepsis and septic shock will also be reviewed.
引用
收藏
页码:235 / 251
页数:17
相关论文
共 50 条
  • [1] INTERLEUKIN-1 AND INTERLEUKIN-1 ANTAGONISM
    DINARELLO, CA
    [J]. JOURNAL OF CELLULAR BIOCHEMISTRY, 1994, : 259 - 259
  • [2] INTERLEUKIN-1 AND INTERLEUKIN-1 ANTAGONISM
    DINARELLO, CA
    [J]. BLOOD, 1991, 77 (08) : 1627 - 1652
  • [3] Interleukin-10 and interleukin-1 receptor antagonist distinguish between patients with sepsis and the systemic inflammatory response syndrome (SIRS)
    Potjo, Moliehi
    Theron, Annette J.
    Cockeran, Riana
    Sipholi, Ndisha N.
    Steel, Helen C.
    Bale, Tsohadi V.
    Meyer, Pieter W. A.
    Anderson, Ronald
    Tintinger, Gregory R.
    [J]. CYTOKINE, 2019, 120 : 227 - 233
  • [4] Interleukin-1 receptor antagonism
    NikolicPaterson, DJ
    Lan, HY
    Atkins, RC
    [J]. SEMINARS IN NEPHROLOGY, 1996, 16 (06) : 583 - 590
  • [5] Interleukin-1 and interleukin-1 receptor antagonist in systemic lupus erythematosus
    Chang, DM
    [J]. IMMUNOLOGICAL INVESTIGATIONS, 1997, 26 (5-7) : 649 - 659
  • [6] INTERLEUKIN-1, INTERLEUKIN-1 RECEPTOR, AND INTERLEUKIN-1 RECEPTOR ANTAGONIST
    ESPAT, NJ
    ROGY, MA
    COPELAND, EM
    MOLDAWER, LL
    [J]. PROCEEDINGS OF THE NUTRITION SOCIETY, 1994, 53 (02) : 393 - 400
  • [7] BLOCKING INTERLEUKIN-1 IN SEPSIS
    DINARELLO, CA
    [J]. JOURNAL OF ENDOTOXIN RESEARCH, 1995, 2 (03): : 157 - 162
  • [8] ROLE OF INTERLEUKIN-1 AND THE THERAPEUTIC POTENTIAL OF INTERLEUKIN-1 RECEPTOR ANTAGONIST IN SEPSIS
    FISHER, CJ
    OPAL, SM
    LOWRY, SF
    SADOFF, JC
    LABRECQUE, JF
    DONOVAN, HC
    LOOKABAUGH, JL
    LEMKE, J
    PRIBBLE, JP
    STROMATT, SC
    VIGERS, GP
    RUSSELL, DA
    THOMPSON, RC
    [J]. CIRCULATORY SHOCK, 1994, 44 (01) : 1 - 8
  • [9] Interleukin-1 and interleukin-1 receptor antagonist in inflammatory bowel disease
    Cominelli, F
    Pizarro, TT
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1996, 10 : 49 - 53
  • [10] Inflammatory response of interleukin-1β and interleukin-6 in septic rats undergoing laparotomy and laparoscopy
    Chang, CK
    Zdon, MJ
    [J]. SURGICAL LAPAROSCOPY ENDOSCOPY & PERCUTANEOUS TECHNIQUES, 2005, 15 (03): : 124 - 128